Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $479000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 20.17% year-over-year to $479000.0; the TTM value through Dec 2025 reached $2.3 million, down 8.76%, while the annual FY2025 figure was $2.3 million, 8.76% down from the prior year.
  • Depreciation & Amortization (CF) reached $479000.0 in Q4 2025 per TNGX's latest filing, down from $602000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $643000.0 in Q3 2024 and bottomed at $200000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $484800.0, with a median of $600000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 101.33% in 2023, then dropped 20.17% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $300000.0 in 2021, then soared by 100.0% to $600000.0 in 2022, then rose by 2.83% to $617000.0 in 2023, then fell by 2.76% to $600000.0 in 2024, then decreased by 20.17% to $479000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $479000.0 in Q4 2025, $602000.0 in Q3 2025, and $600000.0 in Q2 2025.